Log In
Wednesday 22nd November 2017

Cancer drug off NHS list

26th June 2008

The government’s medical advisory body the National Institute for Clinical Health and Excellence (NICE) has advised against the NHS using Avastin after manufacturer Roche declined to answer requests for data on the drug’s clinical and cost effectiveness.

Avastin is used for lung and breast cancer but British patients now look as though they will miss out on the drug after the Swiss pharmaceuticals group refused to cooperate with NICE. The drug has already been rejected by NICE as not being cost effective for bowel cancer.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2017